Appili Therapeutics Brief: Notes U.S. Food and Drug Administration Meeting Request Submitted to Discuss ATI-1801 Registration Strategy
Appili Therapeutics Brief: Notes U.S. Food and Drug Administration Meeting Request Submitted to Discuss ATI-1801 Registration Strategy
Appili Therapeutics简报：已提交美国食品和药品管理局会议请求，讨论ATI-1801注册策略。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册